MCID: CHL149
MIFTS: 44

Childhood Acute Myeloid Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Childhood Acute Myeloid Leukemia

MalaCards integrated aliases for Childhood Acute Myeloid Leukemia:

Name: Childhood Acute Myeloid Leukemia 12 15 17
Paediatric Acute Myeloid Leukaemia 12
Childhood Acute Myeloid Leukaemia 12
Pediatric Acute Myeloid Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0070323
NCIt 49 C9160

Summaries for Childhood Acute Myeloid Leukemia

Disease Ontology : 12 A childhood leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

MalaCards based summary : Childhood Acute Myeloid Leukemia, also known as paediatric acute myeloid leukaemia, is related to acute myeloblastic leukemia with maturation and myeloid sarcoma. An important gene associated with Childhood Acute Myeloid Leukemia is NSD1 (Nuclear Receptor Binding SET Domain Protein 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Thiotepa and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Childhood Acute Myeloid Leukemia

Diseases related to Childhood Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 acute myeloblastic leukemia with maturation 30.8 NPM1 KIT FLT3
2 myeloid sarcoma 30.6 NPM1 KIT FLT3
3 cebpa-associated familial acute myeloid leukemia 30.2 NPM1 KIT FLT3 DNMT3A
4 cytogenetically normal acute myeloid leukemia 30.2 WT1 NPM1 IDH1 FLT3
5 leukemia, acute lymphoblastic 30.1 WT1 PRAME KIT HRAS FLT3 ABCG2
6 mastocytosis 30.1 TET2 KIT FLT3 ASXL1
7 wilms tumor 1 30.0 WT1 PRAME NPM1 KIT HRAS FLT3
8 atypical chronic myeloid leukemia 29.9 TET2 SETBP1 FLT3 ASXL1
9 sarcoma 29.9 WT1 NRAS NPM1 KIT HRAS
10 acute promyelocytic leukemia 29.8 WT1 PRAME NUP98 NRAS NPM1 HRAS
11 refractory anemia 29.7 TET2 ASXL1
12 core binding factor acute myeloid leukemia 29.4 WT1 NRAS KIT HRAS FLT3 ABCG2
13 systemic mastocytosis 29.4 TET2 NRAS KIT IDH1 DNMT3A ASXL1
14 myeloid leukemia 29.3 WT1 TET2 NUP98 NSD1 NRAS NPM1
15 leukemia 29.2 WT1 TET2 NUP98 NSD1 NRAS NPM1
16 acute leukemia 29.1 WT1 SETBP1 PRAME NUP98 NPM1 KIT
17 myeloproliferative neoplasm 28.9 WT1 TET2 NRAS KIT IDH1 HRAS
18 leukemia, acute myeloid 27.9 WT1 TET2 SETBP1 PRAME NUP98 NSD1
19 leukemia, chronic myeloid 27.9 WT1 SETBP1 PRAME NUP98 NRAS NPM1
20 myelodysplastic syndrome 27.9 WT1 TET2 SETBP1 NUP98 NSD1 NRAS
21 acute myeloblastic leukemia without maturation 10.5 NPM1 FLT3
22 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.5 KIT FLT3
23 testicular gonadoblastoma 10.5 WT1 KIT
24 uterine sarcoma 10.4 WT1 KIT
25 colon leiomyosarcoma 10.4 WT1 KIT
26 ovarian mixed germ cell neoplasm 10.4 WT1 KIT
27 conjunctival nevus 10.4 PRAME NRAS
28 wilms tumor 5 10.3
29 hypereosinophilic syndrome, idiopathic 10.3 WT1 KIT
30 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.3 KIT FLT3
31 spastic paraplegia 8 10.3 SETBP1 NSD1
32 thymoma, familial 10.3 KIT HRAS
33 testicular spermatocytic seminoma 10.3 HRAS DNMT3A
34 sotos syndrome 1 10.3 NUP98 NSD3 NSD1 DNMT3A
35 liver leiomyosarcoma 10.3 WT1 KIT
36 weaver syndrome 10.3 NUP98 NSD3 NSD1 DNMT3A
37 wolffian duct adenocarcinoma 10.3 WT1 HRAS
38 ovarian gonadoblastoma 10.3 WT1 KIT
39 down syndrome 10.3
40 childhood leukemia 10.3
41 systemic mastocytosis with associated hematologic neoplasm 10.3 TET2 KIT ASXL1
42 mast cell neoplasm 10.3 KIT FLT3 ASXL1
43 extracutaneous mastocytoma 10.3 TET2 KIT ASXL1
44 acneiform dermatitis 10.3 NRAS HRAS
45 congenital mesoblastic nephroma 10.3 WT1 NRAS KIT
46 sm-ahnmd 10.3 TET2 KIT ASXL1
47 central nervous system melanocytic neoplasm 10.2 NRAS HRAS
48 indolent systemic mastocytosis 10.2 TET2 KIT ASXL1
49 graft-versus-host disease 10.2
50 mixed cell type cancer 10.2 WT1 KIT HRAS

Graphical network of the top 20 diseases related to Childhood Acute Myeloid Leukemia:



Diseases related to Childhood Acute Myeloid Leukemia

Symptoms & Phenotypes for Childhood Acute Myeloid Leukemia

GenomeRNAi Phenotypes related to Childhood Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.72 HRAS
2 Decreased viability GR00055-A-2 9.72 HRAS
3 Decreased viability GR00106-A-0 9.72 NUP98
4 Decreased viability GR00173-A 9.72 FLT3
5 Decreased viability GR00221-A-1 9.72 FLT3 HRAS KIT NRAS
6 Decreased viability GR00221-A-2 9.72 HRAS
7 Decreased viability GR00221-A-3 9.72 HRAS NRAS
8 Decreased viability GR00221-A-4 9.72 FLT3
9 Decreased viability GR00240-S-1 9.72 ABCG2 NUP98
10 Decreased viability GR00249-S 9.72 IDH1 KDM5A NSD3 NUP98
11 Decreased viability GR00301-A 9.72 KIT
12 Decreased viability GR00381-A-1 9.72 WT1
13 Decreased viability GR00386-A-1 9.72 KDM5A NUP98
14 Decreased viability GR00402-S-2 9.72 DNMT3A NSD3 NUP98

MGI Mouse Phenotypes related to Childhood Acute Myeloid Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 ASXL1 DNMT3A FLT3 HRAS IDH1 KDM5A
2 cellular MP:0005384 10.23 ABCG2 ASXL1 DNMT3A FLT3 KDM5A KIT
3 hematopoietic system MP:0005397 10.21 ABCG2 ASXL1 DNMT3A FLT3 IDH1 KDM5A
4 immune system MP:0005387 10.17 ABCG2 ASXL1 DNMT3A FLT3 IDH1 KDM5A
5 endocrine/exocrine gland MP:0005379 10.09 ASXL1 DNMT3A FLT3 HRAS KDM5A KIT
6 mortality/aging MP:0010768 10.06 ASXL1 DNMT3A FLT3 HRAS IDH1 KDM5A
7 liver/biliary system MP:0005370 9.86 ABCG2 ASXL1 KIT MECOM NPM1 NRAS
8 neoplasm MP:0002006 9.65 ASXL1 FLT3 HRAS KDM5A KIT MECOM
9 no phenotypic analysis MP:0003012 9.17 FLT3 HRAS KIT NRAS NSD1 TET2

Drugs & Therapeutics for Childhood Acute Myeloid Leukemia

Drugs for Childhood Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
5
Daunorubicin Approved Phase 3 20830-81-3 30323
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
8
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
9
Idarubicin Approved Phase 3 58957-92-9 42890
10
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
11
Acyclovir Approved Phase 3 59277-89-3 2022
12
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
13
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
14
Mercaptopurine Approved Phase 3 50-44-2 667490
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
17
Thioguanine Approved Phase 3 154-42-7 2723601
18
Tazobactam Approved Phase 3 89786-04-9 123630
19
Vancomycin Approved Phase 3 1404-90-6 14969 441141
20
Piperacillin Approved Phase 3 66258-76-2 43672
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
22
Captopril Approved Phase 3 62571-86-2 44093
23
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
24
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
25
Ribavirin Approved Phase 3 36791-04-5 37542
26
Palivizumab Approved, Investigational Phase 3 188039-54-5
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
28
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
29
Histamine Approved, Investigational Phase 3 51-45-6 774
30
Cyproheptadine Approved Phase 3 129-03-3 2913
31
Mycophenolic acid Approved Phase 3 24280-93-1 446541
32
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
33
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
34 Molgramostim Investigational Phase 2, Phase 3 99283-10-0
35 Hydrocortisone 17-butyrate 21-propionate Phase 3
36 Etoposide phosphate Phase 3
37 Hydrocortisone-17-butyrate Phase 3
38 Hydrocortisone hemisuccinate Phase 3
39
asparaginase Phase 3
40 Gemtuzumab Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 3
42 Cytochrome P-450 CYP3A Inhibitors Phase 3
43 Antibodies Phase 3
44 Antibodies, Monoclonal Phase 3
45 Immunoglobulins Phase 3
46 Tubulin Modulators Phase 3
47 Antimitotic Agents Phase 3
48 Antineoplastic Agents, Immunological Phase 3
49
Hydroxyitraconazole Phase 3
50 valacyclovir Phase 3

Interventional clinical trials:

(show top 50) (show all 266)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2 Unknown status NCT00149162 Phase 3 proleukin
3 Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
4 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
5 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
6 A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
7 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
8 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
9 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
10 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
11 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
12 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
13 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
14 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
15 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
16 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
17 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
18 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
19 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
20 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
21 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
22 A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Completed NCT00136084 Phase 3 Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone;Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
23 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
24 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
25 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
26 Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL) Recruiting NCT00630565 Phase 2, Phase 3 busulfan;cyclophosphamide;dexamethasone;etoposide
27 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
28 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
29 T-cell Depletion In Unrelated Donor Marrow Transplantation Withdrawn NCT00006451 Phase 3 anti-thymocyte globulin;cyclophosphamide;cyclosporine;methotrexate;methylprednisolone
30 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
31 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
32 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
33 The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
34 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
35 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
36 Phase II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric Acute Myeloid Leukemia Unknown status NCT00887042 Phase 1, Phase 2 Fludarabine, Busulfan, Thymoglobulin
37 A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study Completed NCT00002621 Phase 2
38 Feasibility of Granulocyte-Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow From Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant Completed NCT00118326 Phase 1, Phase 2
39 TREATMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING MARROW TRANSPLANTATION FROM UNRELATED DONORS MATCHED FOR HLA OR INCOMPATIBLE FOR ONE HLA LOCUS ANTIGEN Completed NCT00002553 Phase 2 cyclophosphamide
40 An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection Completed NCT00066599 Phase 2 voriconazole
41 A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants Completed NCT00112567 Phase 1, Phase 2 fludarabine phosphate;thiotepa
42 High Dose Chemotherapy And Autologous Peripheral Blood Stem Cell Rescue For High Risk Acute Leukemia Completed NCT00008190 Phase 2 busulfan;cyclophosphamide;etoposide;melphalan
43 Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies Completed NCT00014495 Phase 1, Phase 2 cytarabine
44 A Phase II Study of Gemcitabine (NSC #613327) in Children With Relapsed Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Completed NCT00006462 Phase 2 gemcitabine hydrochloride
45 A Phase II Study of Oral Topotecan in Children With Relapsed Acute Leukemia Completed NCT00003735 Phase 2 topotecan hydrochloride
46 A Phase II Study of Docetaxel (Taxotere) (NSC# 628503, IND# 59,761) in Children With Refractory Leukemias Completed NCT00021242 Phase 2 docetaxel
47 A Phase I/II Trial of Infusional Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Completed NCT00008697 Phase 1, Phase 2 arsenic trioxide
48 Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
49 Transplantation of HLA Haploidentical Marrow Cells After Ex Vivo Exposure to Recipient Alloantigen in Presence of CTLA4-Ig - A Phase II Study of Tolerance Induction in Donor T Cells by Blockade of the CD80/CD86:CD28 Costimulatory Signal Completed NCT00005854 Phase 2 cyclophosphamide;cyclosporine;methotrexate
50 Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors Completed NCT00005622 Phase 2 cyclophosphamide

Search NIH Clinical Center for Childhood Acute Myeloid Leukemia

Genetic Tests for Childhood Acute Myeloid Leukemia

Anatomical Context for Childhood Acute Myeloid Leukemia

MalaCards organs/tissues related to Childhood Acute Myeloid Leukemia:

40
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Neutrophil

Publications for Childhood Acute Myeloid Leukemia

Articles related to Childhood Acute Myeloid Leukemia:

(show top 50) (show all 718)
# Title Authors PMID Year
1
Treatment of Childhood Acute Myeloid Leukemia in Uruguay: Results of 2 Consecutive Protocols Over 20 Years. 61
32068649 2020
2
Regional differences in access to hematopoietic stem cell transplantation among pediatric patients with acute myeloid leukemia. 61
32323913 2020
3
Genetic aberrations involved in relapse of pediatric acute myeloid leukemia: A literature review. 61
32573082 2020
4
Outcome of Core Binding Factor Acute Myeloid Leukemia in Children: A Single-Center Experience. 61
32496446 2020
5
Oral Manifestations and Complications in Childhood Acute Myeloid Leukemia. 61
32575613 2020
6
Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial. 61
32554555 2020
7
Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. 61
32539815 2020
8
LncRNA LINC00909 promotes cell proliferation and metastasis in pediatric acute myeloid leukemia via miR-625-mediated modulation of Wnt/β-catenin signaling. 61
32423818 2020
9
Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia. 61
32429253 2020
10
Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series. 61
30543582 2020
11
The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. 61
32381579 2020
12
Correction: A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. 61
32300185 2020
13
Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia. 61
32187354 2020
14
Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia. 61
32312148 2020
15
Clinical and functional characterization of telomerase variants in patients with pediatric acute myeloid leukemia/myelodysplastic syndrome. 61
32313107 2020
16
Myeloid sarcoma is associated with poor clinical outcome in pediatric patients with acute myeloid leukemia. 61
31919567 2020
17
Clinical Significance of TARP Expression in Pediatric Acute Myeloid Leukemia. 61
32309783 2020
18
Bundles of Auer rods in mature neutrophils in a pediatric acute myeloid leukemia patient with inv(16)(p13.1q22). 61
32338823 2020
19
Outcome of Childhood Acute Myeloid Leukemia With FLT3-ITD Mutation: The Experience of Children's Cancer Hospital Egypt, 2007-17. 61
32473792 2020
20
Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. 61
32343641 2020
21
Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group. 61
31872548 2020
22
A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. 61
31645648 2020
23
PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation. 61
31865541 2020
24
Positive expression of PAX7 indicates poor prognosis of pediatric and adolescent AML patients. 61
31990602 2020
25
Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study. 61
32175698 2020
26
Advances in Pediatric Acute Promyelocytic Leukemia. 61
32024232 2020
27
Phospho-Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia. 61
32072137 2020
28
Long-term outcome of childhood acute myeloid leukemia: A 10-year retrospective cohort study. 61
32308973 2020
29
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML). 61
32050659 2020
30
Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. 61
32079207 2020
31
Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. 61
31815781 2020
32
Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients. 61
31914337 2020
33
MiR-100 regulates cell viability and apoptosis by targeting ATM in pediatric acute myeloid leukemia. 61
31801665 2020
34
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. 61
32029509 2020
35
Deep Transcriptome Sequencing of Pediatric Acute Myeloid Leukemia Patients at Diagnosis, Remission and Relapse: Experience in 3 Malaysian Children in a Single Center Study. 61
32174960 2020
36
Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia. 61
32308588 2020
37
Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. 61
31294507 2020
38
Clinical and hematological correlates of aberrant immunophenotypic profiles in adult and pediatric acute myeloid leukemia at presentation. 61
32362618 2020
39
Acute Pancreatitis Associated With Cytarabine During the Treatment of Pediatric Acute Myeloid Leukemia. 61
31593004 2020
40
Optimum Induction Chemotherapy for Pediatric Acute Myeloid Leukemia: Experience From A Developing Country. 61
32461741 2020
41
PLCB4 upregulation is associated with unfavorable prognosis in pediatric acute myeloid leukemia. 61
31788080 2019
42
miR-342 suppresses the proliferation and invasion of acute myeloid leukemia by targeting Naa10p. 61
31496296 2019
43
Genetic Landscape of Mitochondrial Regulatory Region in Pediatric Acute Myeloid Leukemia: Changes from Diagnosis to Relapse. 61
31687256 2019
44
Opportunities for immunotherapy in childhood acute myeloid leukemia. 61
31808843 2019
45
Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia. 61
31502412 2019
46
Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan. 61
31707119 2019
47
Corrigendum to "Prevalence of germline predisposition gene mutations in pediatric acute myeloid leukemia: Genetic background of pediatric AML" [Leuk. Res. 85 (2019) (October) 106210]. 61
31666185 2019
48
Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia. 61
31662298 2019
49
Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. 61
31350825 2019
50
Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities. 61
31698461 2019

Variations for Childhood Acute Myeloid Leukemia

Expression for Childhood Acute Myeloid Leukemia

Search GEO for disease gene expression data for Childhood Acute Myeloid Leukemia.

Pathways for Childhood Acute Myeloid Leukemia

GO Terms for Childhood Acute Myeloid Leukemia

Cellular components related to Childhood Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 WT1 TET2 SETBP1 PRAME NUP98 NSD3
2 nucleoplasm GO:0005654 9.47 WT1 SETBP1 PRAME NUP98 NSD3 NSD1

Biological processes related to Childhood Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 PRAME NPM1 KIT HRAS FLT3
2 MAPK cascade GO:0000165 9.76 NRAS KIT HRAS FLT3
3 male gonad development GO:0008584 9.69 WT1 KIT KDM5A
4 positive regulation of transcription, DNA-templated GO:0045893 9.63 WT1 NSD3 NSD1 NPM1 MECOM KDM5A
5 methylation GO:0032259 9.62 NSD3 NSD1 MECOM DNMT3A
6 positive regulation of MAP kinase activity GO:0043406 9.54 KIT HRAS FLT3
7 negative regulation of programmed cell death GO:0043069 9.49 MECOM KIT
8 positive regulation of phospholipase C activity GO:0010863 9.43 KIT HRAS
9 histone H3-K36 methylation GO:0010452 9.4 NSD3 NSD1
10 myeloid progenitor cell differentiation GO:0002318 9.26 KIT FLT3
11 hemopoiesis GO:0030097 9.26 MECOM KIT FLT3 ASXL1
12 chromatin organization GO:0006325 9.1 TET2 NSD3 NSD1 KDM5A DNMT3A ASXL1

Molecular functions related to Childhood Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 WT1 TET2 SETBP1 PRAME NUP98 NSD3
2 chromatin binding GO:0003682 9.72 NSD1 NPM1 KDM5A DNMT3A ASXL1
3 methyltransferase activity GO:0008168 9.56 NSD3 NSD1 MECOM DNMT3A
4 histone methyltransferase activity (H3-K36 specific) GO:0046975 9.37 NSD3 NSD1
5 transcription coactivator activity GO:0003713 9.35 NUP98 NSD3 NPM1 KDM5A ASXL1
6 retinoic acid receptor binding GO:0042974 8.8 PRAME NSD1 ASXL1

Sources for Childhood Acute Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....